RxDoctor Payments Data

Charles Eifrig, MD

Retina Specialist · Laguna Hills, CANPI 1306812979

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 60.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $61,522 and has fallen 72.2% since, to $17,088 in 2025. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$281,826in general payments, 2019–2025

Across 431 payments — averaging $653.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$170K
  • Alcon Research LLC$45K
  • Alcon$39K
  • Carl Zeiss Meditec, Inc.$10K
  • AbbVie$7K
  • Regeneron$3K
  • plus $8K from 21 others
$18,000in research payments, 2019–2025

Across 6 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$10K
  • Alcon Research LLC$5K
  • Hexal AG$2K
  • AbbVie$650

What the payments were for

  • Consulting fees$111,36740%
  • Speaking & faculty fees$123,52044%
  • Travel & lodging$30,64011%
  • Food & beverage$16,1496%
  • Education$1310%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$281,826 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$3,677,041
Medicare patients
1,339
Services billed
56,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium21$7,135
Prednisolone Acetate130$3,732
Ketorolac Tromethamine157$3,141
Difluprednate18$1,936
Tobramycin-DexamethasoneTobramycin/Dexamethasone63$1,895
Atropine Sulfate13$326
Timolol Maleate11$109

Paid to pharmacies, not to this prescriber.

Other retina specialist in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →